[February 17, 2017]

Global Meningeal Leukemia API Manufacturers, Marketed and Phase III Drugs Landscape Report 2017 - Research and Markets

Research and Markets has announced the addition of the "Meningeal Leukemia - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017" drug pipelines to their offering.

Meningeal Leukemia - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017, provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturers across the globe.

A key objective of the Meningeal Leukemia Report is to understand the market and pipeline status of the drugs around the Meningeal Leukemia to explore the generic development opportunities, licensing opportunities and to gain competitive advantage on designing pipeline strategies. Te Report provides the historical and forecasted sales of the drugs till 2018.

The Meningeal Leukemia Report gives insights into patents providing the patent protection data and marketing exclusivity of all the drugs across the Meningeal Leukemia.

While the leading brands, companies and chemicals are considered thoroughly, the report also provides details on the Global API Manufacturers across the globe covering Drug Master Filings of US, Europe and API Manufacturers in Asia specifically China and India.

Key Topics Covered:

1. Indication Overview

2. Market Drugs Landscape

3. Global API Manufacturers Assessment

4. Phase III Drugs Landscape

5. Drugs Market Data and Forecasted Sales Figure-2018

6. Marketed Drugs for Meningeal Leukemia

7. Phase III Drugs for Meningeal Leukemia

8. Discontinued Drugs for Meningeal Leukemia

9. Appendix

For more information about this drug pipelines report visit http://www.researchandmarkets.com/research/59p84k/meningeal

View source version on businesswire.com: http://www.businesswire.com/news/home/20170217005488/en/

[ Back To TMCnet.com's Homepage ]